Overview:

Prostate-specific membrane antigen (PSMA)-targeted imaging and radioligand therapies are rapidly transforming the treatment landscape for advanced prostate cancer, especially metastatic castration-resistant prostate cancer. Despite recent FDA approvals and promising data, community oncologists face persistent challenges incorporating these innovations into practice, including patient selection, sequencing of therapies, management of adverse events, and disparities in access to PSMA diagnostics and treatments.

To address these needs, this CME-certified initiative will feature a series of ten 1-hour live virtual meetings, held in conjunction with ACCC State Oncology Chapter Meetings, along with a complementary enduring online activity and social media recaps. Each session will pair national PSMA experts with local community oncologists to facilitate practical, case-based discussions and equip learners with actionable strategies for integrating PSMA-targeted approaches into real-world care.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate the diagnostic and prognostic significance of PSMA PET imaging in advanced prostate cancer and integrate imaging findings into systemic treatment decisions.
• Assess recent clinical trial evidence supporting PSMA-targeted radioligand therapies and determine patient eligibility and optimal timing for initiation within community oncology practice.
• Implement patient-centered strategies for managing PSMA-directed radioligand therapy, including effective sequencing with androgen receptor signaling inhibitors (ARSIs), chemotherapy, and novel combination therapies.
• Identify practical barriers to accessing and delivering PSMA-directed imaging and radioligand therapy in community practice settings and develop collaborative solutions to expand equitable patient access

Target Audience:

This educational program is primarily directed toward community-based oncologists, radiation oncologists, nuclear medicine physicians, advanced practice providers, and other health care professionals involved in the treatment of prostate cancer.

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour. 

Acknowledgment of Educational Support

Have a question for the PER® team?

Email: info@gotoper.com